Centers for Disease Control and Prevention, Atlanta, Georgia, USA.
Marshfield Clinic Research Institute, Marshfield, Wisconsin, USA.
Influenza Other Respir Viruses. 2022 Jul;16(4):673-679. doi: 10.1111/irv.12973. Epub 2022 Feb 15.
Individuals in contact with persons with COVID-19 are at high risk of developing COVID-19; protection offered by COVID-19 vaccines in the context of known exposure is poorly understood.
Symptomatic outpatients aged ≥12 years reporting acute onset of COVID-19-like illness and tested for SARS-CoV-2 between February 1 and September 30, 2021 were enrolled. Participants were stratified by self-report of having known contact with a COVID-19 case in the 14 days prior to illness onset. Vaccine effectiveness was evaluated using the test-negative study design and multivariable logistic regression.
Among 2229 participants, 283/451 (63%) of those reporting contact and 331/1778 (19%) without known contact tested SARS-CoV-2-positive. Adjusted vaccine effectiveness was 71% (95% confidence interval [CI], 49%-83%) among fully vaccinated participants reporting a known contact versus 80% (95% CI, 72%-86%) among those with no known contact (p-value for interaction = 0.2).
This study contributes to growing evidence of the benefits of vaccinations in preventing COVID-19 and support vaccination recommendations and the importance of efforts to increase vaccination coverage.
接触过 COVID-19 患者的人患 COVID-19 的风险很高;在已知接触的情况下,COVID-19 疫苗提供的保护作用了解甚少。
本研究招募了 2021 年 2 月 1 日至 9 月 30 日期间报告急性 COVID-19 样疾病且检测 SARS-CoV-2 呈阳性的年龄≥12 岁的有症状门诊患者。根据发病前 14 天自我报告与 COVID-19 病例的已知接触情况对参与者进行分层。使用阴性对照研究设计和多变量逻辑回归评估疫苗效力。
在 2229 名参与者中,451 名报告接触的参与者中有 283 名(63%)和 1778 名无已知接触的参与者中有 331 名(19%)检测 SARS-CoV-2 呈阳性。与无已知接触者相比,报告有已知接触者的完全接种疫苗者的调整后疫苗效力为 71%(95%可信区间,49%-83%),而无已知接触者的调整后疫苗效力为 80%(95%可信区间,72%-86%)(交互检验的 p 值为 0.2)。
本研究为疫苗在预防 COVID-19 方面的益处提供了更多证据,并支持疫苗接种建议和提高疫苗接种覆盖率的重要性。